Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer

Sheema Khan, Mara C. Ebeling, Neeraj Chauhan, Paul A. Thompson, Rishi K. Gara, Aditya Ganju, Murali M. Yallapu, Stephen W. Behrman, Haotian Zhao, Nadeem Zafar, Man Mohan Singh, Meena Jaggi, Subhash C. Chauhan

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The management of pancreatic ductal adenocarcinoma (PDAC) is extremely poor due to lack of an efficient therapy and development of chemoresistance to the current standard therapy, gemcitabine. Recent studies implicate the intimate reciprocal interactions between epithelia and underlying stroma due to paracrine Sonic hedgehog (SHH) signaling in producing desmoplasia and chemoresistance in PDAC. Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer properties and depletes tumor-associated stromal tissue by inhibiting the SHH signaling pathway in PDAC. We found that ormeloxifene inhibited cell proliferation and induced death in PDAC cells, which provoked us to investigate the combinatorial effects of ormeloxifene with gemcitabine at the molecular level. Ormeloxifene caused potent inhibition of the SHH signaling pathway via downregulation of SHH and its related important downstream targets such as Gli-1, SMO, PTCH1/2, NF-κB, p-AKT, and cyclin D1. Ormeloxifene potentiated the antitumorigenic effect of gemcitabine by 75% in PDAC xenograft mice. Furthermore, ormeloxifene depleted tumor-associated stroma in xenograft tumor tissues by inhibiting the SHH cellular signaling pathway and mouse/human collagen I expression. Xenograft tumors treated with ormeloxifene in combination with gemcitabine restored the tumor-suppressor miR-132 and inhibited stromal cell infiltration into the tumor tissues. In addition, invasiveness of tumor cells cocultivated with TGFb-stimulated human pancreatic stromal cells was effectively inhibited by ormeloxifene treatment alone or in combination with gemcitabine. We propose that ormeloxifene has high therapeutic index and in a combination therapy with gemcitabine, it possesses great promise as a treatment of choice for PDAC/pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)2292-2304
Number of pages13
JournalCancer Research
Volume75
Issue number11
DOIs
StatePublished - Jun 1 2015

Fingerprint

gemcitabine
Pancreatic Neoplasms
Hedgehogs
Adenocarcinoma
Neoplasms
Heterografts
Stromal Cells
ormeloxifene
Cyclin D1
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Khan, S., Ebeling, M. C., Chauhan, N., Thompson, P. A., Gara, R. K., Ganju, A., ... Chauhan, S. C. (2015). Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. Cancer Research, 75(11), 2292-2304. https://doi.org/10.1158/0008-5472.CAN-14-2397

Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. / Khan, Sheema; Ebeling, Mara C.; Chauhan, Neeraj; Thompson, Paul A.; Gara, Rishi K.; Ganju, Aditya; Yallapu, Murali M.; Behrman, Stephen W.; Zhao, Haotian; Zafar, Nadeem; Singh, Man Mohan; Jaggi, Meena; Chauhan, Subhash C.

In: Cancer Research, Vol. 75, No. 11, 01.06.2015, p. 2292-2304.

Research output: Contribution to journalArticle

Khan, S, Ebeling, MC, Chauhan, N, Thompson, PA, Gara, RK, Ganju, A, Yallapu, MM, Behrman, SW, Zhao, H, Zafar, N, Singh, MM, Jaggi, M & Chauhan, SC 2015, 'Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer', Cancer Research, vol. 75, no. 11, pp. 2292-2304. https://doi.org/10.1158/0008-5472.CAN-14-2397
Khan, Sheema ; Ebeling, Mara C. ; Chauhan, Neeraj ; Thompson, Paul A. ; Gara, Rishi K. ; Ganju, Aditya ; Yallapu, Murali M. ; Behrman, Stephen W. ; Zhao, Haotian ; Zafar, Nadeem ; Singh, Man Mohan ; Jaggi, Meena ; Chauhan, Subhash C. / Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer. In: Cancer Research. 2015 ; Vol. 75, No. 11. pp. 2292-2304.
@article{4fb9c59551ba4c798e46b8a65e1e4f71,
title = "Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer",
abstract = "The management of pancreatic ductal adenocarcinoma (PDAC) is extremely poor due to lack of an efficient therapy and development of chemoresistance to the current standard therapy, gemcitabine. Recent studies implicate the intimate reciprocal interactions between epithelia and underlying stroma due to paracrine Sonic hedgehog (SHH) signaling in producing desmoplasia and chemoresistance in PDAC. Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer properties and depletes tumor-associated stromal tissue by inhibiting the SHH signaling pathway in PDAC. We found that ormeloxifene inhibited cell proliferation and induced death in PDAC cells, which provoked us to investigate the combinatorial effects of ormeloxifene with gemcitabine at the molecular level. Ormeloxifene caused potent inhibition of the SHH signaling pathway via downregulation of SHH and its related important downstream targets such as Gli-1, SMO, PTCH1/2, NF-κB, p-AKT, and cyclin D1. Ormeloxifene potentiated the antitumorigenic effect of gemcitabine by 75{\%} in PDAC xenograft mice. Furthermore, ormeloxifene depleted tumor-associated stroma in xenograft tumor tissues by inhibiting the SHH cellular signaling pathway and mouse/human collagen I expression. Xenograft tumors treated with ormeloxifene in combination with gemcitabine restored the tumor-suppressor miR-132 and inhibited stromal cell infiltration into the tumor tissues. In addition, invasiveness of tumor cells cocultivated with TGFb-stimulated human pancreatic stromal cells was effectively inhibited by ormeloxifene treatment alone or in combination with gemcitabine. We propose that ormeloxifene has high therapeutic index and in a combination therapy with gemcitabine, it possesses great promise as a treatment of choice for PDAC/pancreatic cancer.",
author = "Sheema Khan and Ebeling, {Mara C.} and Neeraj Chauhan and Thompson, {Paul A.} and Gara, {Rishi K.} and Aditya Ganju and Yallapu, {Murali M.} and Behrman, {Stephen W.} and Haotian Zhao and Nadeem Zafar and Singh, {Man Mohan} and Meena Jaggi and Chauhan, {Subhash C.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1158/0008-5472.CAN-14-2397",
language = "English (US)",
volume = "75",
pages = "2292--2304",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer

AU - Khan, Sheema

AU - Ebeling, Mara C.

AU - Chauhan, Neeraj

AU - Thompson, Paul A.

AU - Gara, Rishi K.

AU - Ganju, Aditya

AU - Yallapu, Murali M.

AU - Behrman, Stephen W.

AU - Zhao, Haotian

AU - Zafar, Nadeem

AU - Singh, Man Mohan

AU - Jaggi, Meena

AU - Chauhan, Subhash C.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The management of pancreatic ductal adenocarcinoma (PDAC) is extremely poor due to lack of an efficient therapy and development of chemoresistance to the current standard therapy, gemcitabine. Recent studies implicate the intimate reciprocal interactions between epithelia and underlying stroma due to paracrine Sonic hedgehog (SHH) signaling in producing desmoplasia and chemoresistance in PDAC. Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer properties and depletes tumor-associated stromal tissue by inhibiting the SHH signaling pathway in PDAC. We found that ormeloxifene inhibited cell proliferation and induced death in PDAC cells, which provoked us to investigate the combinatorial effects of ormeloxifene with gemcitabine at the molecular level. Ormeloxifene caused potent inhibition of the SHH signaling pathway via downregulation of SHH and its related important downstream targets such as Gli-1, SMO, PTCH1/2, NF-κB, p-AKT, and cyclin D1. Ormeloxifene potentiated the antitumorigenic effect of gemcitabine by 75% in PDAC xenograft mice. Furthermore, ormeloxifene depleted tumor-associated stroma in xenograft tumor tissues by inhibiting the SHH cellular signaling pathway and mouse/human collagen I expression. Xenograft tumors treated with ormeloxifene in combination with gemcitabine restored the tumor-suppressor miR-132 and inhibited stromal cell infiltration into the tumor tissues. In addition, invasiveness of tumor cells cocultivated with TGFb-stimulated human pancreatic stromal cells was effectively inhibited by ormeloxifene treatment alone or in combination with gemcitabine. We propose that ormeloxifene has high therapeutic index and in a combination therapy with gemcitabine, it possesses great promise as a treatment of choice for PDAC/pancreatic cancer.

AB - The management of pancreatic ductal adenocarcinoma (PDAC) is extremely poor due to lack of an efficient therapy and development of chemoresistance to the current standard therapy, gemcitabine. Recent studies implicate the intimate reciprocal interactions between epithelia and underlying stroma due to paracrine Sonic hedgehog (SHH) signaling in producing desmoplasia and chemoresistance in PDAC. Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer properties and depletes tumor-associated stromal tissue by inhibiting the SHH signaling pathway in PDAC. We found that ormeloxifene inhibited cell proliferation and induced death in PDAC cells, which provoked us to investigate the combinatorial effects of ormeloxifene with gemcitabine at the molecular level. Ormeloxifene caused potent inhibition of the SHH signaling pathway via downregulation of SHH and its related important downstream targets such as Gli-1, SMO, PTCH1/2, NF-κB, p-AKT, and cyclin D1. Ormeloxifene potentiated the antitumorigenic effect of gemcitabine by 75% in PDAC xenograft mice. Furthermore, ormeloxifene depleted tumor-associated stroma in xenograft tumor tissues by inhibiting the SHH cellular signaling pathway and mouse/human collagen I expression. Xenograft tumors treated with ormeloxifene in combination with gemcitabine restored the tumor-suppressor miR-132 and inhibited stromal cell infiltration into the tumor tissues. In addition, invasiveness of tumor cells cocultivated with TGFb-stimulated human pancreatic stromal cells was effectively inhibited by ormeloxifene treatment alone or in combination with gemcitabine. We propose that ormeloxifene has high therapeutic index and in a combination therapy with gemcitabine, it possesses great promise as a treatment of choice for PDAC/pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84941226357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941226357&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2397

DO - 10.1158/0008-5472.CAN-14-2397

M3 - Article

C2 - 25840985

AN - SCOPUS:84941226357

VL - 75

SP - 2292

EP - 2304

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 11

ER -